Form 4: Halozyme Therapeutics Director Henderson Acquires Shares and Options

Director Jeffrey William Henderson acquired shares and options in Halozyme Therapeutics as part of the company's director compensation program.

Summary

• On April 25, 2024, Jeffrey William Henderson, a director of Halozyme Therapeutics, acquired 6,501 shares of common stock and an option to purchase 8,804 shares of common stock.
• The acquisition of common stock was an annual restricted stock unit (RSU) grant under the Issuer's director compensation program.
• The RSU grant will vest in full on the earlier of April 25, 2025, and the date of the Issuer's next annual meeting of stockholders.
• The option grant was an annual stock option grant under the Issuer's director compensation program with an exercise price of $38.46.
• This option grant will vest in full on the earlier of April 25, 2025, and the date of the Issuer's next annual meeting of stockholders.
• Following the transaction, Henderson directly owns 53,611 shares of Halozyme Therapeutics common stock and options to purchase 8,804 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence in the company, but it's a routine transaction related to compensation.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting schedule of the RSUs and options aligns the director's interests with those of the shareholders.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical and biotechnology industries as part of executive and director compensation packages. These transactions are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are standard practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation structures to incentivize their directors and executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure long-term alignment with shareholder interests.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
• Employees may view the director's stock ownership as a positive sign of confidence in the company's future.

Key Dates